Compare SPRY & POET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRY | POET |
|---|---|---|
| Founded | 2015 | 1972 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 843.0M |
| IPO Year | 2020 | 2008 |
| Metric | SPRY | POET |
|---|---|---|
| Price | $9.19 | $5.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | 1.1M | ★ 6.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 114.04 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $89,149,000.00 | N/A |
| Revenue This Year | N/A | $2,939.08 |
| Revenue Next Year | $119.97 | $710.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 297063.34 | N/A |
| 52 Week Low | $6.66 | $3.10 |
| 52 Week High | $18.63 | $9.41 |
| Indicator | SPRY | POET |
|---|---|---|
| Relative Strength Index (RSI) | 42.29 | 44.88 |
| Support Level | $8.61 | $5.05 |
| Resistance Level | $10.44 | $5.75 |
| Average True Range (ATR) | 0.50 | 0.39 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 35.48 | 55.45 |
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.